Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19246067 | 0.83 | CA14 (0.36) | CA14SSTR4HDAC1HDAC2HDAC6 | |
| SCHEMBL29746689 | 0.83 | CA14 (0.40) | CA14SSTR4APLNRHDAC1HDAC2 | |
| SCHEMBL19750797 | 0.81 | CA1 (0.41) | CA14SSTR4HDAC1HDAC2HDAC6 | |
| SCHEMBL23817201 | 0.80 | CA14 (0.32) | CA14APLNRHDAC1HDAC2HDAC6 | |
| SCHEMBL24904226 | 0.80 | CA14 (0.32) | CA14APLNRHDAC1HDAC2HDAC6 | |
| SCHEMBL23073608 | 0.78 | CA14 (0.36) | CA14SSTR4HDAC1HDAC2HDAC6 | |
| SCHEMBL19891780 | 0.78 | DPP4 (0.37) | CA14SSTR4HDAC1HDAC2HDAC6 | |
| SCHEMBL23331816 | 0.78 | CA14 (0.36) | CA14SSTR4HDAC1HDAC2HDAC6 | |
| SCHEMBL13715964 | 0.78 | CA14 (0.39) | CA14SSTR4HDAC1HDAC2HDAC6 | |
| SCHEMBL1962792 | 0.76 | MEN1 (0.45) | CA14SSTR4HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183381-B2 | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | METABOLEX INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090137590-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137590-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | CA14 4242/4885SSTR4 81/4885APLNR 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.